Lirum Therapeutics, Inc. (LRTX)
| Market Cap | 45.00M |
| Revenue (ttm) | n/a |
| Net Income | 2.20M +14.7% |
| EPS | 0.24 |
| Shares Out | 9.00M |
| PE Ratio | 20.45 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About LRTX
Lirum Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Our lead product candidate, LX-101, is a novel, clinical stage, next generation, precision-engineered targeted therapy directed to the IGF-1R. The IGF-1/IGF-1R pathway has been implicated in a host of diseases. LX-101 has been clinically evaluated ... [Read more]
Financial Performance
Financial StatementsNews
Oncology and autoimmune biotech Lirum Therapeutics files for a $25 million IPO
Lirum Therapeutics, a Phase 1 biotech developing an in-licensed therapy for cancer and autoimmune diseases, filed on Monday with the SEC to raise up to $25 million in an initial public offering.
Lirum Therapeutics IPO Registration Document (S-1)
Lirum Therapeutics has filed to go public with an IPO on the NASDAQ.